Details of the Drug

General Information of Drug (ID: DM8AI9U)

• Drug Name: Loxapine
• Synonyms: Cloxazepine; Dibenzacepin; Dibenzoazepine; Lossapina; Loxapin; Loxapina; Loxapinsuccinate; Loxapinum; Loxepine; Oxilapine; Lossapina [DCIT]; Loxitane IM; CL 62362; HF 3170; HF3170; Hydrofluoride 3170; LW 3170; S 805; SUM 3170; CL-62362; Loxapac (TN); Loxapina [INN-Spanish]; Loxapinum [INN-Latin]; Loxitane (TN); S-805;SUM-3170; CL-71,563; Loxapine (USAN/INN); Loxapine [USAN:BAN:INN]; Loxapine [USAN:INN:BAN]; 2-Chloro-11-(4-methyl-1-piperazinyl)-dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)oxazepine; 2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,5]benzoxazepine

Indication

Disease Entry	ICD 11	Status	REF
Bipolar disorder	6A60	Approved	[1]
Schizophrenia	6A20	Approved	[2]

• Therapeutic Class: Antipsychotic Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 327.8
  Logarithm of the Partition Coefficient (xlogp); 3.1
  Rotatable Bond Count (rotbonds); 1
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 3
• ADMET Property:
  Half-life: The concentration or amount of drug in body reduced by one-half in 4 hours [3]
  Metabolism: The drug is metabolized via the hepatic []
• Chemical Identifiers:
  Formula: C18H18ClN3O
  IUPAC Name: 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine
  Canonical SMILES: CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl
  InChI: InChI=1S/C18H18ClN3O/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3
  InChIKey: XJGVXQDUIWGIRW-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 3964
  ChEBI ID: CHEBI:50841
  CAS Number: 1977-10-2
  DrugBank ID: DB00408
  TTD ID: D0U5OE
  INTEDE ID: DR0989
  ACDINA ID: D00379
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[4]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[5]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[5]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[5]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Gene/Protein Processing	[6]

Molecular Expression Atlas of This Drug

• The Studied Disease: Bipolar disorder
• ICD Disease Classification: 6A60

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.20E-03	-0.51	-1.35
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	8.46E-01	-6.63E-03	-4.49E-02
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	8.70E-01	2.98E-02	1.22E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.76E-01	1.26E-01	8.27E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Loxapine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Quetiapine	DM1N62C	Moderate	Additive anticholinergic effects by the combination of Loxapine and Quetiapine.	Schizophrenia [6A20]	[7]
Mesoridazine	DM2ZGAN	Moderate	Additive anticholinergic effects by the combination of Loxapine and Mesoridazine.	Schizophrenia [6A20]	[7]
Thioridazine	DM35M8J	Moderate	Additive anticholinergic effects by the combination of Loxapine and Thioridazine.	Schizophrenia [6A20]	[7]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Loxapine and Aripiprazole.	Schizophrenia [6A20]	[7]
Iloperidone	DM6AUFY	Moderate	Additive anticholinergic effects by the combination of Loxapine and Iloperidone.	Schizophrenia [6A20]	[7]
Paliperidone	DM7NPJS	Moderate	Additive anticholinergic effects by the combination of Loxapine and Paliperidone.	Schizophrenia [6A20]	[7]
Haloperidol	DM96SE0	Moderate	Additive anticholinergic effects by the combination of Loxapine and Haloperidol.	Schizophrenia [6A20]	[7]
Perphenazine	DMA4MRX	Moderate	Additive anticholinergic effects by the combination of Loxapine and Perphenazine.	Schizophrenia [6A20]	[7]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Loxapine and Molindone.	Schizophrenia [6A20]	[7]
Chlorpromazine	DMBGZI3	Moderate	Additive anticholinergic effects by the combination of Loxapine and Chlorpromazine.	Schizophrenia [6A20]	[7]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Loxapine and Thiothixene.	Schizophrenia [6A20]	[7]
Trifluoperazine	DMKBYWI	Moderate	Additive anticholinergic effects by the combination of Loxapine and Trifluoperazine.	Schizophrenia [6A20]	[7]
Risperidone	DMN6DXL	Moderate	Additive anticholinergic effects by the combination of Loxapine and Risperidone.	Schizophrenia [6A20]	[7]
Asenapine	DMSQZE2	Moderate	Additive anticholinergic effects by the combination of Loxapine and Asenapine.	Schizophrenia [6A20]	[7]
Pimozide	DMW83TP	Moderate	Additive anticholinergic effects by the combination of Loxapine and Pimozide.	Schizophrenia [6A20]	[7]

Coadministration of a Drug Treating the Disease Different from Loxapine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Loxapine and Oliceridine.	Acute pain [MG31]	[8]
Scopolamine	DMOM8AL	Moderate	Additive anticholinergic effects by the combination of Loxapine and Scopolamine.	Addictive disorder [6C50-6C5Z]	[7]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Loxapine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[9]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Loxapine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[9]
Tripelennamine	DMZBU15	Moderate	Additive anticholinergic effects by the combination of Loxapine and Tripelennamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[7]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Loxapine and Memantine.	Alzheimer disease [8A20]	[7]
Galantamine	DMEO794	Moderate	Antagonize the effect of Loxapine when combined with Galantamine.	Alzheimer disease [8A20]	[10]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Loxapine when combined with Rivastigmine.	Alzheimer disease [8A20]	[10]
Donepezil	DMIYG7Z	Moderate	Antagonize the effect of Loxapine when combined with Donepezil.	Alzheimer disease [8A20]	[10]
Trimethaphan	DMHF4IQ	Moderate	Additive hypotensive effects by the combination of Loxapine and Trimethaphan.	Aneurysm/dissection [BD50]	[11]
Bepridil	DM0RKS4	Moderate	Additive hypotensive effects by the combination of Loxapine and Bepridil.	Angina pectoris [BA40]	[12]
Amyl nitrite	DMJKO05	Moderate	Additive hypotensive effects by the combination of Loxapine and Amyl nitrite.	Angina pectoris [BA40]	[12]
Nifedipine	DMSVOZT	Moderate	Additive hypotensive effects by the combination of Loxapine and Nifedipine.	Angina pectoris [BA40]	[12]
Hydroxyzine	DMF8Y74	Moderate	Additive anticholinergic effects by the combination of Loxapine and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[7]
Promazine	DMZAL7W	Moderate	Additive anticholinergic effects by the combination of Loxapine and Promazine.	Appearance/behaviour symptom [MB23]	[7]
Desipramine	DMT2FDC	Moderate	Additive anticholinergic effects by the combination of Loxapine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[7]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Loxapine and Cariprazine.	Bipolar disorder [6A60]	[7]
Loperamide	DMOJZQ9	Moderate	Additive antimotility effects by the combination of Loxapine and Loperamide.	Bowel habit change [ME05]	[13]
Sotalol	DML60TN	Moderate	Additive hypotensive effects by the combination of Loxapine and Sotalol.	Cardiac arrhythmia [BC9Z]	[12]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Loxapine when combined with Acetylcholine.	Cataract [9B10]	[14]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Loxapine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[15]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Loxapine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[15]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Loxapine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[15]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Loxapine and Dihydrocodeine.	Chronic pain [MG30]	[16]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Loxapine and Olopatadine.	Conjunctiva disorder [9A60]	[17]
Alfentanil	DMVO0UB	Major	Additive CNS depression effects by the combination of Loxapine and Alfentanil.	Corneal disease [9A76-9A78]	[8]
Remifentanil	DMZTXCH	Major	Additive CNS depression effects by the combination of Loxapine and Remifentanil.	Corneal disease [9A76-9A78]	[8]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Loxapine and Ethanol.	Cystitis [GC00]	[17]
Cyclandelate	DMO0R76	Moderate	Additive hypotensive effects by the combination of Loxapine and Cyclandelate.	Dementia [6D80-6D8Z]	[12]
Trimipramine	DM1SC8M	Moderate	Additive anticholinergic effects by the combination of Loxapine and Trimipramine.	Depression [6A70-6A7Z]	[7]
Cyclobenzaprine	DM1YBRM	Moderate	Additive anticholinergic effects by the combination of Loxapine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[7]
Nortriptyline	DM4KDYJ	Moderate	Additive anticholinergic effects by the combination of Loxapine and Nortriptyline.	Depression [6A70-6A7Z]	[7]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Loxapine and OPC-34712.	Depression [6A70-6A7Z]	[7]
Clomipramine	DMINRKW	Moderate	Additive anticholinergic effects by the combination of Loxapine and Clomipramine.	Depression [6A70-6A7Z]	[7]
Amoxapine	DMKITQE	Moderate	Additive anticholinergic effects by the combination of Loxapine and Amoxapine.	Depression [6A70-6A7Z]	[7]
Doxepin	DMPI98T	Moderate	Additive anticholinergic effects by the combination of Loxapine and Doxepin.	Depression [6A70-6A7Z]	[7]
Maprotiline	DMPWB7T	Moderate	Additive anticholinergic effects by the combination of Loxapine and Maprotiline.	Depression [6A70-6A7Z]	[7]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Loxapine and Esketamine.	Depression [6A70-6A7Z]	[18]
Hyoscyamine	DM804UR	Moderate	Additive anticholinergic effects by the combination of Loxapine and Hyoscyamine.	Digestive system disease [DE2Z]	[7]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Loxapine and Mepenzolate.	Digestive system disease [DE2Z]	[7]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Loxapine and Oxybutynine.	Discovery agent [N.A.]	[7]
Tetrabenazine	DMYWQ0O	Major	Additive antidopaminergic effects by the combination of Loxapine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[19]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Loxapine and Deutetrabenazine.	Dystonic disorder [8A02]	[20]
Zonisamide	DM0DTF7	Major	Increased risk of hyperpyrexia by the combination of Loxapine and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[21]
Diphenhydramine	DMKQTBA	Moderate	Antagonize the effect of Loxapine when combined with Diphenhydramine.	Episodic vestibular syndrome [AB31]	[22]
Guanabenz	DM5QWEL	Moderate	Additive hypotensive effects by the combination of Loxapine and Guanabenz.	Essential hypertension [BA00]	[12]
Ethacrynic acid	DM60QMR	Moderate	Additive hypotensive effects by the combination of Loxapine and Ethacrynic acid.	Essential hypertension [BA00]	[11]
Bendroflumethiazide	DM7EVLC	Moderate	Additive hypotensive effects by the combination of Loxapine and Bendroflumethiazide.	Essential hypertension [BA00]	[12]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Loxapine and Phenoxybenzamine.	Essential hypertension [BA00]	[12]
Guanethidine	DM9NSWT	Moderate	Additive hypotensive effects by the combination of Loxapine and Guanethidine.	Essential hypertension [BA00]	[12]
Nicardipine	DMCDYW7	Moderate	Additive hypotensive effects by the combination of Loxapine and Nicardipine.	Essential hypertension [BA00]	[12]
Mecamylamine	DMGQFYB	Moderate	Additive hypotensive effects by the combination of Loxapine and Mecamylamine.	Essential hypertension [BA00]	[12]
Benzthiazide	DMQWZ0H	Moderate	Additive hypotensive effects by the combination of Loxapine and Benzthiazide.	Essential hypertension [BA00]	[12]
Nadolol	DMW6GVL	Moderate	Additive hypotensive effects by the combination of Loxapine and Nadolol.	Essential hypertension [BA00]	[12]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Loxapine and Solifenacin.	Functional bladder disorder [GC50]	[7]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Loxapine and Tolterodine.	Functional bladder disorder [GC50]	[7]
Darifenacin	DMWXLYZ	Moderate	Decreased metabolism of Loxapine caused by Darifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[23]
Phentolamine	DMXYJOB	Moderate	Additive hypotensive effects by the combination of Loxapine and Phentolamine.	Gangrene [MC85]	[12]
Propantheline	DM2EN6G	Moderate	Additive anticholinergic effects by the combination of Loxapine and Propantheline.	Gastric ulcer [DA60]	[7]
Isoflurophate	DMBSK7X	Moderate	Antagonize the effect of Loxapine when combined with Isoflurophate.	Glaucoma [9C61]	[14]
Carteolol	DMFMDOB	Moderate	Additive hypotensive effects by the combination of Loxapine and Carteolol.	Glaucoma [9C61]	[12]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Loxapine and Brimonidine.	Glaucoma [9C61]	[24]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Loxapine when combined with Pilocarpine.	Glaucoma [9C61]	[14]
Spironolactone	DM2AQ5N	Moderate	Additive hypotensive effects by the combination of Loxapine and Spironolactone.	Heart failure [BD10-BD1Z]	[12]
Prazosin	DMCD9YG	Moderate	Additive hypotensive effects by the combination of Loxapine and Prazosin.	Heart failure [BD10-BD1Z]	[12]
Eplerenone	DMF0NQR	Moderate	Additive hypotensive effects by the combination of Loxapine and Eplerenone.	Heart failure [BD10-BD1Z]	[12]
Carvedilol	DMHTEAO	Moderate	Additive hypotensive effects by the combination of Loxapine and Carvedilol.	Heart failure [BD10-BD1Z]	[12]
Chlorothiazide	DMLHESP	Moderate	Additive hypotensive effects by the combination of Loxapine and Chlorothiazide.	Heart failure [BD10-BD1Z]	[12]
Furosemide	DMMQ8ZG	Moderate	Additive hypotensive effects by the combination of Loxapine and Furosemide.	Heart failure [BD10-BD1Z]	[12]
Amiloride	DMRTSGP	Moderate	Additive hypotensive effects by the combination of Loxapine and Amiloride.	Heart failure [BD10-BD1Z]	[12]
Bumetanide	DMRV7H0	Moderate	Additive hypotensive effects by the combination of Loxapine and Bumetanide.	Heart failure [BD10-BD1Z]	[12]
Hydroflumethiazide	DMVPUQI	Moderate	Additive hypotensive effects by the combination of Loxapine and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[12]
Acebutolol	DM0TI4U	Moderate	Additive hypotensive effects by the combination of Loxapine and Acebutolol.	Hypertension [BA00-BA04]	[12]
Moexipril	DM26E4B	Moderate	Additive hypotensive effects by the combination of Loxapine and Moexipril.	Hypertension [BA00-BA04]	[12]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Loxapine and Captopril.	Hypertension [BA00-BA04]	[12]
Penbutolol	DM4ES8F	Moderate	Additive hypotensive effects by the combination of Loxapine and Penbutolol.	Hypertension [BA00-BA04]	[12]
Methyldopa	DM5I621	Moderate	Additive hypotensive effects by the combination of Loxapine and Methyldopa.	Hypertension [BA00-BA04]	[12]
Clonidine	DM6RZ9Q	Moderate	Additive hypotensive effects by the combination of Loxapine and Clonidine.	Hypertension [BA00-BA04]	[12]
Losartan	DM72JXH	Moderate	Additive hypotensive effects by the combination of Loxapine and Losartan.	Hypertension [BA00-BA04]	[12]
Nebivolol	DM7F1PA	Moderate	Additive hypotensive effects by the combination of Loxapine and Nebivolol.	Hypertension [BA00-BA04]	[12]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Loxapine and Levamlodipine.	Hypertension [BA00-BA04]	[12]
Fosinopril	DM9NJ52	Moderate	Additive hypotensive effects by the combination of Loxapine and Fosinopril.	Hypertension [BA00-BA04]	[12]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Loxapine and TAK-491.	Hypertension [BA00-BA04]	[12]
Pindolol	DMD2NV7	Moderate	Additive hypotensive effects by the combination of Loxapine and Pindolol.	Hypertension [BA00-BA04]	[12]
Fenoldopam	DMFAOKP	Moderate	Additive hypotensive effects by the combination of Loxapine and Fenoldopam.	Hypertension [BA00-BA04]	[12]
Indapamide	DMGN1PW	Moderate	Additive hypotensive effects by the combination of Loxapine and Indapamide.	Hypertension [BA00-BA04]	[12]
Benazepril	DMH1M9B	Moderate	Additive hypotensive effects by the combination of Loxapine and Benazepril.	Hypertension [BA00-BA04]	[12]
Trichlormethiazide	DMHAQCO	Moderate	Additive hypotensive effects by the combination of Loxapine and Trichlormethiazide.	Hypertension [BA00-BA04]	[12]
Labetalol	DMK8U72	Moderate	Additive hypotensive effects by the combination of Loxapine and Labetalol.	Hypertension [BA00-BA04]	[12]
Diazoxide	DML1538	Moderate	Additive hypotensive effects by the combination of Loxapine and Diazoxide.	Hypertension [BA00-BA04]	[12]
Perindopril	DMOPZDT	Moderate	Additive hypotensive effects by the combination of Loxapine and Perindopril.	Hypertension [BA00-BA04]	[12]
Quinapril	DMR8H31	Moderate	Additive hypotensive effects by the combination of Loxapine and Quinapril.	Hypertension [BA00-BA04]	[12]
Deserpidine	DMRH7CV	Moderate	Additive hypotensive effects by the combination of Loxapine and Deserpidine.	Hypertension [BA00-BA04]	[12]
Telmisartan	DMS3GX2	Moderate	Additive hypotensive effects by the combination of Loxapine and Telmisartan.	Hypertension [BA00-BA04]	[12]
Irbesartan	DMTP1DC	Moderate	Additive hypotensive effects by the combination of Loxapine and Irbesartan.	Hypertension [BA00-BA04]	[12]
Hydralazine	DMU8JGH	Moderate	Additive hypotensive effects by the combination of Loxapine and Hydralazine.	Hypertension [BA00-BA04]	[12]
Lisinopril	DMUOK4C	Moderate	Additive hypotensive effects by the combination of Loxapine and Lisinopril.	Hypertension [BA00-BA04]	[12]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Loxapine and Clevidipine butyrate.	Hypertension [BA00-BA04]	[12]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Loxapine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[7]
Amantadine	DMS3YE9	Moderate	Additive anticholinergic effects by the combination of Loxapine and Amantadine.	Influenza [1E30-1E32]	[25]
Propiomazine	DMKY8V1	Moderate	Additive anticholinergic effects by the combination of Loxapine and Propiomazine.	Insomnia [7A00-7A0Z]	[7]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Loxapine and ITI-007.	Insomnia [7A00-7A0Z]	[7]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Loxapine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[26]
Clidinium	DMUMQZ0	Moderate	Additive anticholinergic effects by the combination of Loxapine and Clidinium.	Irritable bowel syndrome [DD91]	[7]
Dicyclomine	DMZSDGX	Moderate	Additive anticholinergic effects by the combination of Loxapine and Dicyclomine.	Irritable bowel syndrome [DD91]	[7]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Loxapine when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[10]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Loxapine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[27]
Propranolol	DM79NTF	Moderate	Additive hypotensive effects by the combination of Loxapine and Propranolol.	Migraine [8A80]	[12]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Loxapine and Lasmiditan.	Migraine [8A80]	[28]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Loxapine and Flibanserin.	Mood disorder [6A60-6E23]	[29]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Loxapine and Thalidomide.	Multiple myeloma [2A83]	[30]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Loxapine and Phenindamine.	Nasopharyngitis [CA00]	[7]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Loxapine and Dimenhydrinate.	Nausea/vomiting [MD90]	[7]
Prochlorperazine	DM53SRA	Moderate	Additive anticholinergic effects by the combination of Loxapine and Prochlorperazine.	Nausea/vomiting [MD90]	[7]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Loxapine and Promethazine.	Nausea/vomiting [MD90]	[7]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Loxapine and Cyclizine.	Nausea/vomiting [MD90]	[7]
Metoclopramide	DMFA5MY	Major	Additive antidopaminergic effects by the combination of Loxapine and Metoclopramide.	Nausea/vomiting [MD90]	[31]
Lorcaserin	DMG6OYJ	Moderate	Increased risk of hyperprolactinemic effects by the combination of Loxapine and Lorcaserin.	Obesity [5B80-5B81]	[32]
Metolazone	DMB39LO	Moderate	Additive hypotensive effects by the combination of Loxapine and Metolazone.	Oedema [MG29]	[12]
Polythiazide	DMCH80F	Moderate	Additive hypotensive effects by the combination of Loxapine and Polythiazide.	Oedema [MG29]	[12]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Loxapine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[16]
Lofexidine	DM1WXA6	Moderate	Additive hypotensive effects by the combination of Loxapine and Lofexidine.	Opioid use disorder [6C43]	[12]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Loxapine and Apraclonidine.	Optic nerve disorder [9C40]	[24]
Pentazocine	DM1XBHS	Major	Additive CNS depression effects by the combination of Loxapine and Pentazocine.	Pain [MG30-MG3Z]	[8]
Dextropropoxyphene	DM23HCX	Major	Decreased metabolism of Loxapine caused by Dextropropoxyphene mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[33]
Butorphanol	DM5KYPJ	Major	Additive CNS depression effects by the combination of Loxapine and Butorphanol.	Pain [MG30-MG3Z]	[8]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Loxapine and Oxymorphone.	Pain [MG30-MG3Z]	[8]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Loxapine and Levorphanol.	Pain [MG30-MG3Z]	[8]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Loxapine and Dezocine.	Pain [MG30-MG3Z]	[8]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Loxapine and Flavoxate.	Pain [MG30-MG3Z]	[7]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Loxapine and Nalbuphine.	Pain [MG30-MG3Z]	[8]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Loxapine and Buprenorphine.	Pain [MG30-MG3Z]	[34]
Meperidine	DMX4GND	Major	Additive CNS depression effects by the combination of Loxapine and Meperidine.	Pain [MG30-MG3Z]	[8]
Oxycodone	DMXLKHV	Major	Additive CNS depression effects by the combination of Loxapine and Oxycodone.	Pain [MG30-MG3Z]	[8]
Pergolide	DM14MAE	Moderate	Antagonize the effect of Loxapine when combined with Pergolide.	Parkinsonism [8A00]	[35]
Opicapone	DM1BKA6	Moderate	Antagonize the effect of Loxapine when combined with Opicapone.	Parkinsonism [8A00]	[35]
Biperiden	DME78OA	Moderate	Antagonize the effect of Loxapine when combined with Biperiden.	Parkinsonism [8A00]	[22]
Entacapone	DMLBVKQ	Moderate	Antagonize the effect of Loxapine when combined with Entacapone.	Parkinsonism [8A00]	[35]
Levodopa	DMN3E57	Moderate	Additive CNS depression effects by the combination of Loxapine and Levodopa.	Parkinsonism [8A00]	[35]
Pramipexole	DMNMW9R	Moderate	Antagonize the effect of Loxapine when combined with Pramipexole.	Parkinsonism [8A00]	[35]
Bromocriptine	DMVE3TK	Moderate	Additive hypotensive effects by the combination of Loxapine and Bromocriptine.	Parkinsonism [8A00]	[35]
Apomorphine	DMX38HQ	Moderate	Antagonize the effect of Loxapine when combined with Apomorphine.	Parkinsonism [8A00]	[36]
Lindane	DMB8CNL	Moderate	Increased risk of lowers seizure threshold by the combination of Loxapine and Lindane.	Pediculosis [1G00]	[37]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Loxapine and Methylscopolamine.	Peptic ulcer [DA61]	[7]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Loxapine and Terazosin.	Prostate hyperplasia [GA90]	[12]
Tamsulosin	DM5QF9V	Moderate	Additive hypotensive effects by the combination of Loxapine and Tamsulosin.	Prostate hyperplasia [GA90]	[12]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Loxapine and Silodosin.	Prostate hyperplasia [GA90]	[12]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Loxapine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[7]
Fluphenazine	DMIT8LX	Moderate	Additive anticholinergic effects by the combination of Loxapine and Fluphenazine.	Psychotic disorder [6A20-6A25]	[7]
Tolazoline	DMI40NL	Moderate	Additive hypotensive effects by the combination of Loxapine and Tolazoline.	Pulmonary hypertension [BB01]	[12]
Neupro	DMHEAB1	Moderate	Antagonize the effect of Loxapine when combined with Neupro.	Restless legs syndrome [7A80]	[35]
Cyproheptadine	DM92AH3	Moderate	Additive anticholinergic effects by the combination of Loxapine and Cyproheptadine.	Rheumatoid arthritis [FA20]	[7]
Fentanyl	DM8WAHT	Major	Additive CNS depression effects by the combination of Loxapine and Fentanyl.	Sensation disturbance [MB40]	[8]
Sufentanil	DMU7YEL	Major	Additive CNS depression effects by the combination of Loxapine and Sufentanil.	Sensation disturbance [MB40]	[8]
Papaverine	DMCA9QP	Moderate	Additive hypotensive effects by the combination of Loxapine and Papaverine.	Tonus and reflex abnormality [MB47]	[12]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Loxapine and Tizanidine.	Tonus and reflex abnormality [MB47]	[38]
Atropine	DMEN6X7	Moderate	Additive anticholinergic effects by the combination of Loxapine and Atropine.	Unspecific substance harmful effect [NE6Z]	[7]
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Loxapine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[7]
Methdilazine	DMAUHQX	Moderate	Additive anticholinergic effects by the combination of Loxapine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[7]
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Loxapine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[9]
Brompheniramine	DMFOVSD	Moderate	Additive anticholinergic effects by the combination of Loxapine and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[7]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Loxapine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[7]
Azatadine	DMZ80SB	Moderate	Additive anticholinergic effects by the combination of Loxapine and Azatadine.	Vasomotor/allergic rhinitis [CA08]	[7]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Benzyl alcohol	E00010	244	Antimicrobial preservative; Solvent
Butylparaben	E00142	7184	Antimicrobial preservative
D&C red no. 28	E00491	6097185	Colorant
D&C red no. 33	E00261	19116	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
methylparaben	E00149	7456	Antimicrobial preservative
Propyl 4-hydroxybenzoate	E00141	7175	Antimicrobial preservative
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Carmellose sodium	E00625	Not Available	Disintegrant
Edetate calcium disodium	E00487	6093170	Complexing agent
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Gelatin	E00630	Not Available	Other agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium propionate	E00445	2723816	Antimicrobial preservative
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Loxapine 10 mg capsule	10 mg	Oral Capsule	Oral
Loxapine 25 mg capsule	25 mg	Oral Capsule	Oral
Loxapine 5 mg capsule	5 mg	Oral Capsule	Oral
Loxapine 50 mg capsule	50 mg	Oral Capsule	Oral
Loxapine Succinate eq 10mg base capsule	eq 10mg base	Capsule	Oral
Loxapine Succinate eq 5mg base capsule	eq 5mg base	Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Loxapine FDA Label
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [4] Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis. Clin Neuropharmacol. 1995 Feb;18(1):39-45.
• [5] In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos. 2011 Oct;32(7):398-407.
• [6] Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
• [7] Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
• [8] Cerner Multum, Inc. "Canadian Product Information.".
• [9] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
• [10] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
• [11] Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
• [12] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
• [13] Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
• [14] Multum Information Services, Inc. Expert Review Panel.
• [15] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
• [16] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [17] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [18] Cerner Multum, Inc. "Australian Product Information.".
• [19] Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
• [20] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [21] Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
• [22] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]
• [23] Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
• [24] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [25] Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
• [26] Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
• [27] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [28] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [29] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [30] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [31] Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
• [32] Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
• [33] Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
• [34] Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
• [35] Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
• [36] Product Information. Apokyn (apomorphine). Mylan Pharmaceuticals Inc, Morgantown, WV.
• [37] Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
• [38] Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.